Bayer plans to beef up biotech pipeline
Bayer Healthcare says it will aggressively expand its biotech pipeline in the year ahead, concentrating on new development pacts in cardiology, hematology and oncology. The company is looking to strike new deals similar to the ones it has reached with Nuvelo and Onyx Pharmaceuticals. Hans Bishop, the former senior v.p. for Chiron's UK operations, will likely head up many of these new ventures. Bishop is expected to be tapped as the next president of the company's hematology and cardiology business after Joe Akers retires.
- here's the report on Bayer from the East Bay Business Journal
Related Articles:
Bayer sells subsidiary in €1.2B deal. Report
Bayer Schering outlines global R&D restructuring. Report
Bayer outbids Merck KGaA for Schering. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets